Western Blotting (WB), ELISA, Immunofluorescence (IF)
Specificity
DR3 has no cross reaction to other death receptors.
Purification
DR3 Antibody is Antibody is DEAE purified.
Immunogen
DR3 antibody was raised against a 16 amino acid peptide near the amino terminus of human DR3. The immunogen is located within the first 50 amino acids of DR3.
DR3 antibody can be used for detection of DR3 by Western blot 1 μ,g/mL. A 59 kDa band can be detected.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
DR3 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
DR3 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
DR3/LARD (TNFRSF25)
(Tumor Necrosis Factor Receptor Superfamily, Member 25 (TNFRSF25))
DR3 Antibody: Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified by several groups independently and designated DR3, Wsl-1, Apo-3, TRAMP and LARD1-5. The ligand for this novel death receptor has been defined as TWEAK, also termed Apo3L. DR3 is highly expressed in the tissues enriched in lymphocytes including PBL, thymus and spleen. Like TNFR1, DR3 induces apoptosis and NF-κ,B activation.